Tudorza Pressair

Aclidinium bromide (INN) is a long-acting, inhaled muscarinic antagonist (LAMA) approved in the United States on July 24, 2012[1] as a maintenance treatment for chronic obstructive pulmonary disease (COPD).[2] Evidence shows that it can improve quality of life and prevent hospitalization in those with COPD.[3] However, it does not appear to affect the risk of death or the frequency steroids are needed.[3] It is unclear if it diff... [wikipedia]